会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 15. 发明授权
    • Pharmaceutical compositions
    • 药物组合物
    • US4587240A
    • 1986-05-06
    • US651772
    • 1984-09-18
    • Robert C. HiderGeorge KontoghiorghesJack SilverMichael A. Stockham
    • Robert C. HiderGeorge KontoghiorghesJack SilverMichael A. Stockham
    • A61K31/44A61P3/00A61P7/06C07D213/89C07F15/02C07D213/69A61K31/555
    • C07D213/89C07F15/025
    • Compounds which are a 1-hydroxypyrid-2-one in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by a substituent selected from aliphatic acyl, aliphatic amide, aliphatic amine, carboxy, cyano, aliphatic ester, halogen, hydroxy and sulpho groups, alkoxy groups and alkoxy groups substituted by an alkoxy, aliphatic amide, aliphatic amine, aliphatic ester, halogen or hydroxy group, aliphatic hydrocarbon groups and aliphatic hydrocarbon groups substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by substituents selected from aliphatic hydrocarbon groups, halogen groups and aliphatic hydrocarbon groups substituted by a halogen group, or a salt thereof containing a physiolgically acceptable ion or ions, are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body whilst the iron complexes of such compounds are of value in the treatment of iron deficiency anaemia.
    • 其中一个或多个连接到环碳原子上的氢原子被选自脂族酰基,脂族酰胺,脂族胺,羧基,氰基,脂肪族酯,卤素中的取代基取代的1-羟基吡啶-2-酮的化合物, 被烷氧基,脂族酰胺,脂族胺,脂族酯,卤素或羟基取代的烷氧基和烷氧基,被烷氧基,脂族酯,卤素或羟基取代的脂族烃基和脂族烃基,但是 不包括化合物中氢原子置换的化合物只能由选自脂族烃基,卤素基团和被卤素基团取代的脂族烃基的取代基或其含有生理上可接受的离子或离子的盐所取代, 在治疗身体中有毒浓度的金属,特别是铁的患者中, 这些化合物在治疗缺铁性贫血方面是有价值的。
    • 16. 发明授权
    • Pharmaceutical compositions
    • 药物组合物
    • US4585780A
    • 1986-04-29
    • US592271
    • 1984-03-22
    • Robert C. HiderGeorge KontoghiorghesJack Silver
    • Robert C. HiderGeorge KontoghiorghesJack Silver
    • C09K3/00A61K31/44A61K31/4406A61K31/4412A61K31/4418A61K31/4425A61K31/4427A61M1/36A61P3/00A61P39/02C07D213/69C07D213/70C07D213/75C07D309/40C07D401/12A61K31/555
    • C07D213/69
    • Pharmaceutical compositions containing a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, or a salt thereof containing a physiologically acceptable ion or ions, are of value for removing toxic amounts of metals, particularly iron, from the body.
    • 含有与氮原子连接的氢原子被脂肪族酰基,脂肪族烃基或被脂肪族烃基取代的3-羟基吡啶-2-酮或3-羟基吡啶-4-酮的药物组合物 除了可离子化基团之外,还有多于一个选自脂族酰基,烷氧基,脂族胺,脂族酰胺,羧基,脂族酯,卤素,羟基和磺基的取代基,以及任选地,其中一个或多个 与环碳原子连接的氢原子被一个所述取代基,脂族烃基或被烷氧基,脂族酯,卤素或羟基取代的脂族烃基所取代,但不包括其中所述氢取代的化合物 化合物中的原子仅由脂族烃基或其含有生理上可接受的离子或离子的盐进行,对于除去有毒量的我是有价值的 来自身体的东西,特别是铁。